Existing computational methods for drug repositioning either rely only on the gene expression response of cell lines after treatment, or on drug-to-disease relationships, merging several information levels. However, the noisy nature of the gene expression and the scarcity of genomic data for many diseases are important limitations to such approaches. Here we focused on a drug-centered approach by predicting the therapeutic class of FDA-approved compounds, not considering data concerning the diseases. We propose a novel computational approach to predict drug repositioning based on state-of-the-art machine-learning algorithms. We have integrated multiple layers of information: i) on the distances of the drugs based on how similar are their chemical structures, ii) on how close are their targets within the protein-protein interaction network, and iii) on how correlated are the gene expression patterns after treatment. Our classifier reaches high accuracy levels (78%), allowing us to re-interpret the top misclassifications as re-classifications, after rigorous statistical evaluation. Efficient drug repurposing has the potential to significantly impact the whole field of drug development. The results presented here can significantly accelerate the translation into the clinics of known compounds for novel therapeutic uses.

Drug repurposing involves the identification of new applications for existing drugs at a lower cost and in a shorter time. There are different computational drug-repurposing strategies and some of these approaches have been applied to the coronavirus disease 2019 (COVID-19) pandemic. Computational drug-repositioning approaches applied to COVID-19 can be broadly categorized into (i) network-based models, (ii) structure-based approaches and (iii) artificial intelligence (AI) approaches. Network-based approaches are divided into two categories: network-based clustering approaches and network-based propagation approaches. Both of them allowed to annotate some important patterns, to identify proteins that are functionally associated with COVID-19 and to discover novel drug–disease or drug–target relationships useful for new therapies. Structure-based approaches allowed to identify small chemical compounds able to bind macromolecular targets to evaluate how a chemical compound can interact with the biological counterpart, trying to find new applications for existing drugs. AI-based networks appear, at the moment, less relevant since they need more data for their application.

Diabetes is a chronic, metabolic disease characterized by high blood sugar levels. Among the main types of diabetes, type 2 is the most common. Early diagnosis and treatment can prevent or delay the onset of complications. Previous studies examined the application of machine learning techniques for prediction of the pathology, and here an artificial neural network shows very promising results as a possible valuable aid in the management and prevention of diabetes. Additionally, its superior ability for long-term predictions makes it an ideal choice for this field of study. We utilized machine learning methods to uncover previously undiscovered associations between an individual’s health status and the development of type 2 diabetes, with the goal of accurately predicting its onset or determining the individual’s risk level. Our study employed a binary classifier, trained on scratch, to identify potential nonlinear relationships between the onset of type 2 diabetes and a set of parameters obtained from patient measurements. Three datasets were utilized, i.e., the National Center for Health Statistics’ (NHANES) biennial survey, MIMIC-III and MIMIC-IV. These datasets were then combined to create a single dataset with the same number of individuals with and without type 2 diabetes. Since the dataset was balanced, the primary evaluation metric for the model was accuracy. The outcomes of this study were encouraging, with the model achieving accuracy levels of up to 86% and a ROC AUC value of 0.934. Further investigation is needed to improve the reliability of the model by considering multiple measurements from the same patient over time.

Predicting volatility is a critical activity for taking risk- adjusted decisions in asset trading and allocation. In order to provide effective decision-making support, in this paper we investigate the profitability of a deep Long Short-Term Memory (LSTM) Neural Network for forecasting daily stock market volatility using a panel of 28 assets representative of the Dow Jones Industrial Average index combined with the market factor proxied by the SPY and, separately, a panel of 92 assets belonging to the NASDAQ 100 index. The Dow Jones plus SPY data are from January 2002 to August 2008, while the NASDAQ 100 is from December 2012 to November 2017. If, on the one hand, we expect that this evolutionary behavior can be effectively captured adaptively through the use of Artificial Intelligence (AI) flexible methods, on the other, in this setting, standard parametric approaches could fail to provide optimal predictions. We compared the volatility forecasts generated by the LSTM approach to those obtained through use of widely recognized benchmarks models in this field, in particular, univariate parametric models such as the Realized Generalized Autoregressive Conditionally Heteroskedastic (R-GARCH) and the Glosten–Jagannathan–Runkle Multiplicative Error Models (GJR-MEM). The results demonstrate the superiority of the LSTM over the widely popular R-GARCH and GJR-MEM univariate parametric methods, when forecasting in condition of high volatility, while still producing comparable predictions for more tranquil periods.